This breakthrough offers a game-changing solution to vaccine hesitancy and accessibility challenges. The floss-based method eliminates needle phobia concerns while providing superior mucosal immunity compared to traditional injections. It's simple, cost-effective and could be distributed by mail during pandemics without requiring medical professionals.
The technology raises serious concerns about consent and coercion in mass vaccination campaigns. If floss-based vaccines become widespread, they could be administered without public awareness or proper oversight. The potential for adding vaccines to everyday products like toothpaste creates alarming possibilities for bypassing individual health autonomy.
There's a 95% chance that before Jan. 1, 2032, an intranasal SARS-CoV-2 vaccine candidate will be approved by the U.S., U.K., EU or Canada, according to the Metaculus prediction community.